Table 6 Association between genotypes of MMP9, 2 and 3 and SCLC patients' survival of CAPUA study
From: Genetic polymorphisms in MMP 2, 9 and 3genes modify lung cancer risk and survival
Genotypes | Patients | Deaths | MST (months) | Crude HR | 95% CI | HRa | 95% CI |
|---|---|---|---|---|---|---|---|
MMP9 | n = 129 | ||||||
C/C | 98 | 88 | 9.5 | 1.00 | 1.00 | ||
C/T | 28 | 25 | 8.9 | 1.08 | 0.69-1.69 | 1.06 | 0.67-1.68 |
T/T | 3 | 3 | 24.5 | 0.67 | 0.21-2.12 | 0.97 | 0.29-3.25 |
MMP2 | n = 140 | ||||||
C/C | 112 | 102 | 8.8 | 1.00 | 1.00 | ||
C/T | 27 | 24 | 8.9 | 0.90 | 0.58-1.41 | 0.98 | 0.60-1.58 |
T/T | 1 | 1 | 9.2 | 1.34 | 0.19-9.70 | 1.25 | 0.17-9.31 |
MMP3 | n = 116 | ||||||
6A/6A | 37 | 34 | 7.6 | 1.00 | 1.00 | ||
6A/5A | 61 | 54 | 9.4 | 0.84 | 0.55-1.30 | 0.79 | 0.50-1.26 |
5A/5A | 18 | 16 | 13.4 | 0.69 | 0.37-1.26 | 0.67 | 0.35-1.27 |